Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.

The returning client is a midsize US pharma company developing inhaled therapies. The customer has decided to test another one of its inhaled drug formulation candidates using ISAB's preclinical in vitro testing module DissolvIt, following successful results from its previous IRS /DissolvIt project. The new project is worth EUR 98,000.

According to feedback received from the client, DissolvIt is the first in vitro dissolution method they have found that generated data of such quality that it enabled them to make reliable 'go/no-go' decisions on which formulations to proceed with in the early stages of drug development. Predicting failure at the preclinical stage can produce huge savings in a market where, according to a 2020 study, the average cost of getting a new drug onto the market through all stages of drug development is USD 1.3. The discriminative power of ISAB's DissolvIt technology in comparing small differences between drug formulations aimed for administration via inhalation, is currently being evaluated in an FDA BAA (Broad Agency Announcement) contract research project being carried out at ISAB's facilities in Sweden.